MIRIKIZUMAB - A NEW OPTION IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

被引：0

作者：

Olszewski, Jakub ^{[1
]}

Kozon, Katarzyna ^{[1
]}

Sitnik, Magdalena ^{[1
]}

Herjan, Katarzyna ^{[2
]}

Mikolap, Karolina ^{[3
]}

Gastol, Bartlomiej ^{[4
]}

Bara, Maciej ^{[5
]}

Armanski, Piotr ^{[6
]}

Sawczuk, Marcin ^{[7
]}

机构：

[1] Masovian Brodnowski Hosp, PL-03242 Warsaw, Poland

[2] Prof W Orlowski Mem Hosp, PL-00401 Warsaw, Poland

[3] Wolski Hosp Warsaw, PL-01211 Warsaw, Poland

[4] Masovian Specialist Hosp Ostroleka, PL-07410 Ostroleka, Poland

[5] Med Univ Warsaw, Infant Jesus Clin Hosp, PL-02005 Warsaw, Poland

[6] Dist Hosp Sochaczew, PL-96500 Sochaczew, Poland

[7] Med Univ Gdansk, Clin Ctr, PL-80952 Gdansk, Poland

来源：

PROSPECTS IN PHARMACEUTICAL SCIENCES | 2024年 / 22卷 / 03期

关键词：

mirikizumab; IL-23; ulcerative colitis; ULCERATIVE-COLITIS; MAINTENANCE THERAPY; INTERLEUKIN-23; DIAGNOSIS; INDUCTION;

D O I：

10.56782/pps.262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Mirikizumab is a humanized monoclonal antibody targeting the p19 subunit of interleukin IL-23. Over the past few years, it has been the subject of clinical trials as a potential new treatment for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Additionally, mirikizumab has been investigated in clinical trials as a potential treatment for plaque psoriasis. The results of clinical trials for mirikizumab in treating ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for treating adult patients with moderately to severely active ulcerative colitis. Despite promising clinical trial results, mirikizumab has not yet been approved for the treatment of Crohn's disease. This review focuses on summarizing the findings from clinical trials of mirikizumab in the treatment of inflammatory bowel diseases. Information is sourced from scientific papers available on PubMed, by searching for "mirikizumab" and "IL-23" and published to March 2024, as well as from published results of clinical trials concerning mirikizumab.

引用

页码：178 / 185

页数：8

共 50 条

[41] Personalized medicine in the treatment of inflammatory bowel diseases
Parfenov, A. I.
Knyazev, O. V.
Kagramanova, A. V.
Fadeeva, N. A.
TERAPEVTICHESKII ARKHIV, 2018, 90 (02): : 4 - 11
[42] The treatment of the rheumatological manifestations of the inflammatory bowel diseases
Melissa Padovan
Gabriella Castellino
Marcello Govoni
Francesco Trotta
Rheumatology International, 2006, 26 : 953 - 958
[43] Azathioprine in the treatment of chronic inflammatory bowel diseases
Herrlinger, K
Stange, EF
MEDIZINISCHE KLINIK, 2000, 95 (04) : 201 - 206
[44] INTRAVENOUS HYPERALIMENTATION - IN TREATMENT OF INFLAMMATORY DISEASES OF BOWEL
VOGEL, CM
CORWIN, TR
BAUE, AE
ARCHIVES OF SURGERY, 1974, 108 (04) : 460 - 467
[45] DRUG-TREATMENT OF INFLAMMATORY BOWEL DISEASES
JENSS, H
MEDIZINISCHE WELT, 1987, 38 (18): : 639 - 642
[46] Surgical treatment of inflammatory bowel diseases and pregnancy
Ilnyckyj, Alexandra
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2007, 21 (05) : 819 - 834
[47] SURGICAL TREATMENT OF INFLAMMATORY DISEASES OF LARGE BOWEL
LOCKHARTMUMMERY, HE
PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1970, 63 : 64 - +
[48] Mechanisms and treatment of diarrhea in inflammatory bowel diseases
Urayama, S
Chang, EB
INFLAMMATORY BOWEL DISEASES, 1997, 3 (02) : 114 - 131
[49] Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases
Herfarth, Hans H.
Kappelman, Michael D.
Long, Millie D.
Isaacs, Kim L.
INFLAMMATORY BOWEL DISEASES, 2016, 22 (01) : 224 - 233
[50] Established conservative treatment of inflammatory bowel diseases
Stange, EF
NON-NEOPLASTIC DISEASES OF THE ANORECTUM: AN INTERDISCIPLINARY APPROACH, 2001, 118 : 147 - 150

← 1 2 3 4 5 →